https://www.selleckchem.com/products/az191.html
i. -3·3 to -0·5) months per species; P=0·009). Adjuvant treatment with gemcitabine improved PFS in patients who were negative for K. pneumoniae (26·2 versus 15·3 months; P =0·039), but not in those who tested positive (19·5 versus 13·2 months; P =0·137). Quinolone treatment was associated with improved median overall survival (OS) independent of K. pneumoniae status (48·8 versus 26·2 months; P =0·006) and among those who tested positive for K. pneumoniae (median not reached versus 18·8 months; P =0·028). Patients with quinolone-resistant
Like
Comment
Share
